Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabilizing earnings, and improved sentiment, midcaps experienced growth in the third quarter. The Federal Reserve’s decision to cut rates helped small and mid-cap stocks in the quarter. Value stocks outperformed their growth counterparts with the Russell Midcap Value Index returning 6.2% compared to the Russell Midcap Growth’s 2.8% return. In this environment, the strategy outperformed its Russell Midcap Index during the third quarter. Stock selection in the consumer staples and healthcare sectors drove outperformance of the strategy. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, ClearBridge Mid Cap Strategy highlighted stocks such as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers and commercializes therapeutics based on ribonucleic acid interference. The one-month return of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was -3.73%, and its shares gained 75.54% of their value over the last 52 weeks. On November 12, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock closed at $452.74 per share, with a market capitalization of $59.81 billion.

ClearBridge Mid Cap Strategy stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its third quarter 2025 investor letter:

“Health care was another key driver of outperformance, anchored by strength in biotechnology and the addition of new opportunities in life sciences tools. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) also advanced, driven by accelerating uptake of its treatment for transthyretin cardiac amyloidosis (ATTR-CM) and a raise to full-year revenue guidance, reinforcing confidence in its commercial execution and deep RNA-based drug pipeline.”

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the second quarter, which was 59 in the previous quarter. In the third quarter of 2025, the product revenue of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew 103% year-over-year to $851 million. While we acknowledge the risk and potential of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and shared the list of most promising biotech stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.